|
Fluvastatin |
|
Fig. 1. Nicotinic acid 10 mM ; and probenecid 1 mM ; were employed as inhibitors of the monocarboxylic acid transporter MCT ; and the multidrug resistanceassociated protein MRP ; , respectively, to study the possible involvement of these carriers in the intestinal transport of fluvastatin 1.6 M ; in the rat.
Order fluvastatin
It started on the 23rd. Although the stove's hair was shoulder length at the moment, it had almost cut it just this morning. A neighborhood boy was spying on this lovely oven with a lustful eye, but the wolf was lurking in the bushes. I told my stove it should show off its good looks and the boy stepped right inside. The butcher Abbas showed us how to cook a pullet with the new propane tank I installed as the oven's conscience. He was marinated in lemon juice and tempura sauce with a seasoning of garlic, pepper, and cinnamon, and tasted of rotten cheese. What we threw up, we also ate. Having tasted human flesh the previous day, the phantom double which possessed the oven finally awakened. Though dimmed by connections with earthly metal and plastic, this phantom used an ingenious arrangement of springs that caused the appliance to imitate the lifestyle of a death row inmate. It went into violent convulsions and detached fingers materialized from its timer to pick up pencils and write death threats. To appease the spirit, I found a medium who could open the clit of communication. The charlatan turned on all four grills and claimed the astral body was presenting itself. No, in fact the spirit in question was generated by the oven's growing nervous system. Phantom limbs reached out to hang the wooden spiritualist on a hook. That night we watched television alone, anticipating an explosion tomorrow. I felt my brain grow dizzy on the 25th. Oven rolled toward me and laid its metal skin against me. Its touch was like hot coals pressed upon my spinal column. I couldn't take the pain a second longer, so I covered my face and cried. In a moment of insane fright, I achieved an incredible altitude from which I shoved fatal. The oven fell off the roof and crushed.
Table 4 denotes the Tg values of the various samples. In the case of MWCNT filled samples, the solution mixed composites exhibited a sharp decrease in Tg values for the 10 and 20 wt.% loadings. The melt-mixed composites had negligible changes in Tg values. But in the cases of CNFs and EGs, samples showed very little change in Tg values. The addition of nanofillers improved the temperature of 5 wt.% loss as determined by TGA. Neat UltemTM lost 5 wt.% at 2 4805 C, while the filled samples lost the same weight at temperatures 6 5005 C. No significant differences in thermo-oxidative stability were observed for the melt-mixed and solution-mixed samples.
Saquinavir capsule 200 mg Losartan potassium 100 mg + Hydrochlorothiazide 25 mg tablet Alendronate Na tablet 10 mg, 70 mg Fosfomycin sodium injection 1 gm, 2 gm Nadroparin calcium injection 3, 800 iu anti-Xa 0.4 ml, 5, 700 iu anti-Xa 0.6 ml Sodium fusidate tablet 250 mg Enfuvirtide injection 108 mg Gemcitabine HCl injection 1 gm, 200 mg Menatetrenone capsule 15 mg Carmustine injection 7.7 mg Imatinib mesilate tablet 100 mg, 400 mg Acarbose tablet 50 mg, 100 mg Terlipressin injection 1 mg Follitropin alfa 1050 iu 1.75 ml injection Follitropin alfa 300 iu 0.5 ml injection Follitropin alfa 450 iu 0.75 ml injection Follitropin alfa 600 iu 1 ml injection Follitropin alfa 900 iu 1.5 ml injection Lenograstrim 100 mcg, 250 mcg ; vial for injection Polygeline 3.5 %, 500 ml Ifosfamide injection 500 mg Tamsulosin capsule 0.2 mg Sodium hyaluronate solution for intraocular 14 mg ml in 0.55 ml, 0.85 ml Adefovir dipivoxil tablet 10 mg Trastuzumab injection 150 mg, 440 mg Sodium ioxaglate + Meglumine ioxaglate Insulin Lispro injection Topotecan 4 mg injection Hydroxyurea capsule 500 mg Rilmenidine tablet 1 mg Terazosin tablet 2 mg, 5 mg Losartan potassium 50 mg + Hydrochlorothiazide 12.5 mg tablet Sodium hyaluronate injection pre -filled syringe 20 mg 1.1 ml Floctafenine tablet 200 mg Iloprost 20 mcg ml injection Sumatriptan tablet 50 mg Cilazapril tablet 2.5 mg, 5 mg Tinzaparin sodium injection 10, 000 iu anti-Xa ml in 2-ml Hexobendene 20 mg + Ethamivan 50 mg + Etofylline 60 mg tablet Eptifibatide injection 0.75 mg ml 100 ml, 2 mg ml 10 ml Interferon alfa-2b 18, 000, 000 units solution for injection Interferon alfa-2b 30, 000, 000 units solution for injection Ertapenem sodium injection 1 gm Saquinavir tablet 500 mg Gefitinib tablet 250 mg Verapamil HCl sustained release tablet 240 mg Lopinavir 133.3 mg + Ritonavir 33.3 mg capsule Lopinavir 80 mg + Ritonavir 20 mg in 1 ml oral solution Levetiracetam tablet 250 mg, 500 mg Granisetron tablet 1 mg Lamotrigine tablet 25 mg, 50 mg, 100 mg Terbinafine tablet 250 mg Digoxin elixir 0.05 mg ml , 60 ml Digoxin injection 0.5 mg 2 ml Insulin glargine injection optiset pen 100 IU ml in Thioguanine tablet 40 mg Fluvastatin tablet 20 mg, 40 mg Fluvastatin tablet 80 mg Vardenafil tablet 10 mg, 20 mg : 3 7.
Eight trials reported on secondary prevention in patients with diabetes. The first, the Scandinavian Simvastatin Survival Study 4S ; , randomly assigned patients with coronary disease to simvastatin, 20 mg, or placebo 18 ; . In secondary analysis of the 202 patients with diabetes, simvastatin led to large benefits relative risk for cardiovascular events, 0.50 [CI, 0.33 to 0.76]; absolute risk reduction, 0.23 [CI, 0.10 to 0.35] ; . Of note is the relatively high event rate in the control group 45% ; compared with those seen in other trials. The Cholesterol and Recurrent Events CARE ; trial randomly assigned patients with previous myocardial infarction to pravastatin, 40 mg d, or placebo 19 ; . Pravastatin improved CHD outcomes in the 586 patients with diabetes relative risk for cardiovascular events, 0.78 [CI, 0.62 to 0.99]; absolute risk reduction, 0.08 [CI, 0.01 to 0.16] ; . Results were reported as stratified by baseline LDL cholesterol levels and showed that for the overall study sample, those with baseline levels below 3.23 mmol L 125 mg dL ; did not benefit from lipid-lowering therapy while those with LDL cholesterol levels of at least 3.23 mmol L 125 mg dL ; benefited substantially. The small sample size precluded a similar stratified analysis in the patients with diabetes. The HPS examined the impact of lipid-lowering therapy in secondary prevention in 20 536 patients with coronary disease, other occlusive arterial disease, or diabetes 15 ; . Treatment was with simvastatin, 40 mg d, or placebo. There was no dose adjustment by baseline lipid levels. Among patients with diabetes, the relative risk for any cardiovascular event was 0.89 CI, 0.79 to 1.00 ; in the simvastatin group, and the absolute risk reduction was 0.04 CI, 0.00 to 0.09 ; . The Long-Term Intervention with Pravastatin in Ischemic Disease LIPID ; trial randomly assigned patients with known heart disease to pravastatin, 40 mg d, or placebo 20 ; . In the subgroup of 782 patients with diabetes, the relative risk for a cardiovascular event was 0.84 CI, 0.64 to 1.11 ; and the absolute risk reduction was 0.04 CI, 0.02 to 0.09 ; . Neither of these was statistically significant. The Lescol Intervention Prevention Study LIPS ; was a trial conducted in patients who had undergone percutaneous coronary intervention 21 ; . Researchers randomly assigned patients to fluvastatin, 80 mg d, or placebo. In the 202 patients with type 2 diabetes, fluvastatin was effective in preventing CHD events relative risk, 0.53 [CI, 0.29 to 0.97]; absolute risk reduction, 0.16 [CI, 0.03 to 0.29] ; . The PostCoronary Artery Bypass Graft Post-CABG.
For improving compliance. Curr Med Res Opin 2004; 20: 165 Finnish Statistics on Medicines 2003. Helsinki: National Agency for Medicines and KELA Social Insurance Institution ; 2004. Schwandt P, Brady AJ. Achieving lipid goals in Europe: how large is the treatment gap? Expert Rev Cardiovasc Ther 2004; 2: 431 Teeling M, Bennett K, Feely J. The influence of guidelines on the use of statins: analysis of prescribing trends 19982002. Br J Clin Pharmacol 2005; 59: 22732. Folino-Gallo P, Addis A, Bruzzone M, Confonti A, Moretti U, Leone R, Tosolini F, Velo G. L'assistenza farmaceutica territoriale. In: Folino-Gallo P, Ricciardi G eds ; . Osservasalute Report 2003. Milan: Vita & Pensiero, 2003. European Commission. EuroMed Database: : euromedicines Accessed: 4 March 2005 ; . Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen MJ. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 1994; 343: 1554 Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet 1998; 352: 18301. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia the CURVES study ; . J Cardiol 1998; 81: 5827. Jones P, Davidson M, Stein E, Bays H, McKenney J, Miller E, Cain V, Blasetto J, STELLAR udy Group Comparison of the efficacy, safety of rosuvastatin versus atorvastatin simvastatin, pravastatin across doses. STELLAR Trial ; J Cardiol 2003; 92: 15260. Evan A, Stein E, Strutt K, Southworth H, Diggle P, Miller E, He FH, Study Group. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. J Cardiol 2003; 92: 128793. Davidson M, Palmisano J, Wilson H, Liss C, Dicklin M. A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg d with fluvastatin 20 and 40 mg d. Clinical Therapeutics 2003 25: 27382753. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 90510. EuroMedStat project. The Library of European Union Pharmaceutical Indicators: : euromedstat.cnr.it indicators indicators Accessed: 4 March 2005 and focalin.
The Journal of Immunology that may be exposed to very high concentrations of NE after injection of Ag in vivo. It has been estimated that the concentration of NE that is reached at such nerve terminal endings is between 0.3 and 3 mM 35 ; Therefore, the concentrations used in this study are well below the maximal concentration that a naive T cell may see in vivo. Because naive T cells may see a range of NE during their initial activation in vivo, we exposed naive T cells to a range of concentrations and found that naive T cells exposed to concentrations of NE at and 10 6 M during Th1 differentiation generate Th1 cells that produce more IFN- after restimulation see Fig. 3 ; . In studies that have assayed for the ability of endogenous factors to either positively or negatively influence Th1 differentiation, the increase in IFN- was due to an increase in the number of IFN-producing cells 28, 36 ; . We sought in this study to determine whether a similar mechanism was responsible for the NE-induced increase in IFN- after restimulation. The data suggest a unique model in which Th1 cells that are generated in the presence of NE produce more IFN- per cell. There is a paucity of data in the literature showing that treatment of a naive T cell can influence the amount of a cytokine produced per cell after restimulation. It is possible that NE positively regulates factors that influence the accessibility of the IFN- promoter in naive T cells, which is inherited in the subsequent Th1 effector cells. This possibility is supported by data showing that PGE2 exposure of naive CD4 T cells during differentiation influences the methylation status of the IFN- promoter, as well as the level of IFN- produced after restimulation by the resultant Th1 cells 25 ; . Our experimental design allowed us to determine the effect of NE when the individual components required for Th1 differentiation were limiting. Our data indicate that NE does not independently promote Th1 differentiation, but rather influences IL-12directed differentiation to generate Th1 cells that produce more IFN- after restimulation. Likewise, another factor, IFN inducing factor IGIF ; has been shown to augment IL-12-directed Th1 differentiation to produce Th1 cells that produce more IFN- 37 ; . Although the modulation of IL-12-directed Th1 differentiation may be modest in both cases, increases in the amount of IFNproduced locally may have a profound effect in vivo. The finding that NE requires IL-12 to modulate Th1 differentiation suggests that stimulation of the 2AR on naive T cells may affect a component of the IL-12 pathway to result in an increased Th1 differentiation. These results are in contrast to the findings of previous studies showing that exposure to other cAMP-elevating ligands, such as PGE2, during activation of human PBMCs by anti-CD3 mAb, decreases the expression of both chains of the IL-12 receptor and thus responsiveness to IL-12 38 ; . However, because sorted naive cells were not used in these studies, PGE2 may have acted on cell types other than naive CD4 T cells, e.g., memory and effector CD4 T cells, CD8 T cells, and NK cells 39 ; . Also, in this published study, IL-12 was not added to cultures during the initial activation of the human PBMCs 38 ; , a fact which may be important because a recent report suggests that the presence of IL-12 during CD4 T cell activation may influence the level of IL-12R expression 40 ; . Therefore, differences in the ability of endogenous ligands to influence Th1 differentiation may be dependent on the cytokine milieu in which naive T cells reside during initial activation and differentiation. In addition, our results suggest that the endogenous level of IL-12 produced by APC in vitro is necessary and sufficient for NE to influence Th1 differentiation in response to peptide Ag. Furthermore, exposure of naive T cells and APC to NE did not influence IL-12 production by APC when presenting peptide in the context of MHC II to the naive T cell Fig. 7C ; . This is in contrast to a.
As already mentioned under 5.1.3., a cooperation project between the Departments of Justice and Public Health was set up. A pilot study is expected to start in 2003 on drugs seized in the Judicial District of Antwerp and follistim.
For more information and label information synonyms and keywords authors and editors fluvastatin lescol ; information lescol is the brand name.
The B10.RIII mice were made susceptible to EAU by injecting 50 g IRBPp emulsified with CFA containing 3.0 mg ml M. tuberculosis H37RA into their footpad, base of tail, and back, subcutaneously [18]. On the same day of the immunization, mice were i.v. injected with 2 105 Treg cells from the 24-h cultures prepared above. The uveoretinitis was clinically assessed every 3 days by ocular fundus examination. Before the fundus examination, the pupils were dilated with 0.5% Tropicamide and 2.5% phenylephrine. The severity of inflammation was clinically graded on a scale of 0 5 Table 1 and formoterol.
CI, confidence interval. a Equation 1a: AUC ratio v I ; v control ; 1 I Cmax total; Ki total. b Equation 1b. The free fractions for the inhibitor Iu ; and Ki Ki, u ; are used. c Equation 3: AUC ratio 1 fm 1 fluvastatin eq. 4: AUC ratio.
|
Accidents were the most frequent cause. Thirty-one cases were of the ` ` upper ` ` or uchenne-Erb" type. One-third of these presented an almost complete recovery within a year of the accident. No ; improvement was shown in 10 per cent. Twelve cases gave evidence of injury to the whole plexus. Forty-two per cent of these showed no recovery ; the rest showed improvement in regions innervated by the upper roots. Thirteen cases were atypical ; two-thirds of these 8 per cent ; presented improvement or complete recovery and about one-third no alteration. In twelve cases an operative exploration of the plexus was done without any improvement. The use of homologous transplants from the bone bank-Dr E. Thomasen Aarhus ; reported! 228 operations performed since 1949 at the orthopaedic hospital, Aarhus, with the use of human bone from a deep-freeze bone bank. Bone was obtained mainly from amputations at other hospitals, and was fetched directly from the operation theatres and immediately frozen by carbonic acid before transport to the bank. Most of the operations were fusions of the spine for scoliosis or other spine lesions. Ninety per cent healed without any complication and a further 6 per cent showed only slight unwanted reaction. Dr Thomasen was satisfied with the osteogenetic property of the transplant. Congenital pseudarthrosis of tibia and bowing of diaphyslal bones-Dr E. Thi'ge Madsen Copenhagen ; gave a survey of the literature concerning etiology and treatment of pseudarthrosis and congenital angulation of the tibia and other diaphysial bones. He believed l ; uraiswami's experimental studies of skeletal abnormalities suggested that the conditions were of identical nature. Concerning treatment of pseudarthrosis of the tibia, he believed McFarland's ` ` by-pass ` ` bone grafting to be the best. Radiographs of cases were shown. Treatment of spastic paralysis-Dr P. G. K. Bentzon Aarhus ; gave his ideas on the role of training and physiotherapy of spastic children versus orthopaedic treatment. He believed that the latter was most helpful, and that it should not be dismissed entirely as advocated from some clinics and forteo.
Aggressive monitoring including mixed venous oximetry and serum lactate to assess interventions. Following brain death, free tri-iodothyronine T3 ; , thyroxine T4 ; , cortisol and insulin levels are reduced. A secondary reduction in glucose, pyruvate and palmitate utilization results in the accumulation of lactate and free fatty acids inducing a shift from aerobic to anaerobic metabolism. This shift has been shown to be reversed with the administration of T3.112, 113 A.
BIAC agrees with the OECD's recent findings that the growth in IPRs during the last decade corresponds to new structural innovations, such as public-private partnerships and new business models that are based more on knowledge networks and markets. Innovation processes throughout the OECD have become more competitive, more cooperative, more globalised, and more reliant on new entrants with competitive ideas and products. It, therefore, becomes much more critical that IPRs and competition policy be viewed as complementary policy tools and not as a "zero sum" game. The recent major report by the Federal Trade Commission in the United States, "To Promote Innovation: The Proper Balance of Competition and Patent Law and Policy" aims to strike a balance between monopoly and disclosure. It expresses the realisation that patent offices have often assumed an incorrect attitude by considering applicants as their clients, rather than assume the role of guardian of the public interest. As a result, they have granted too many poor quality patents that stifle innovation. 2.6.1 Recommendations: Provide a comprehensive overview of the current research and policy reviews in member countries, including the European Union, about the intersection of IPRs and competition policy and fortovase.
| WJZD FM Radio Station received two Gold Awards at the Mississippi Association of Broadcasters Awards Luncheon in Jackson on July 26, 2006. The station won "Best of Show" Special or Specific News Event and for its "Coverage of a Special or Specific News Event". Both awards were for WJZD's live coverage of Hurricane Katrina. WJZD was the last station left on air that August 29th morning. Rip Daniels stayed on air live with extended hours of "It's A New Day" morning talk show during the storm taking calls from and giving advice and information to stranded citizens. Gulfport Police and Fire Departments called in to encourage callers to give their address so that help could be sent to them when the storm was over. Radio station WJZD stands at the top of the broadcasting field in the Gulfport-Biloxi area, the second largest market in the state. Thanks to owner Rip Daniels, veteran of 30 years in radio, the FM news-talk-music outlet has consistently held on to the number one or number two position in the important GulportBiloxi market since finding its identity and niche soon after coming under Daniels' ownership in 1993. Daniels is on the air every day hosting "It's A New Day", the two-hour call-in program that is the most popular talk show on the Gulf Coast. His innovative American Blues Network has been such a success that it won the Network of the Year honors in August from the International Black Broadcasters Association. Daniels feels that the paucity of black-owned all over the state is an anomaly. He grew up in a different world, he says. In addition to "JZ 94.5", Rip Daniels whose given name is Stanley also owns Daniels Real Estate Company and the American Blues Forasmuch then as Christ hath suffered for us in the flesh, arm yourselves likewise with the same mind: for he that hath suffered in the flesh hath ceased from sin; That he no longer should live the rest of his time in the flesh to the lusts of men, but to the will of God. 1Peter 4: 1-2 Network, a satellite feed system to over 40 different markets in North America and beyond. "The American Blues Network is targeted to listeners who crave the raw rhythmic beats and soulwrenching lyrics of real "rhythm and Rip Daniels blues, " Daniels says. "It's a healthy mix that runs the gamut from traditional bluesmen like Muddy Waters to the contemporary sounds of artists like Mel Waiters." Rip is married and the father of three grown children, Daniels has worked at nearly every radio station along the Gulf Coast. He is a veteran of some memorable years spent at WJMI and WOKJ in Jackson. A college dropout from Florida's Eckerd College, Daniels is still studying intermittently at the University of Southern Mississippi, but he doesn't regret having forsaken the business degree he was pursuing in the Florida school. Information compile from Earnest McBride article and Judy Lombard Barkum. 228 ; 8965307 x 104.
400 filmtab , efalizumab , efavirenz , eloxatin , emend , emend 3-day , engerix-b , engerix-b pediatric , enoxacin , ery-tab , eryc , eryped , eryped 200 , eryped 400 , erythrocin lactobionate , erythrocin stearate filmtab , erythrocot , erythromycin , erythromycin base , erythromycin estolate , erythromycin ethylsuccinate , erythromycin lactobionate , erythromycin stearate , ethambutol , ethionamide , ethotoin , evoxac , factive , fasigyn , filgrastim , fk506 , flagyl , flagyl 375 , flagyl er , flagyl , flagyl rtu , floxin , floxin , fluarix , fluconazole , fludara , fludarabine , flulaval , fluogen , flushield , flushield obsolete ; , fluvastatin , fluvastatin extended release , fluvirin , fluvirin preservative-free , fluvoxamine , fluzone , fluzone pfs , fluzone preservative-free , fluzone preservative-free pediatric , fluzone sv , fluzone wv , fortovase , fosamprenavir , fosphenytoin , furadantin , g-csf , gadobenate dimeglumine , ganciclovir , gardasil , gatifloxacin , gemifloxacin , gleevec , gm-csf , gold sodium thiomalate , grepafloxacin , haemophilus b conjugate hboc ; vaccine , haemophilus b conjugate prp-omp ; vaccine , haemophilus b conjugate prp-t ; vaccine , haemophilus b conjugate vaccine obsolete ; , haemophilus b diphtheria conjugate vaccine , haemophilus b neisseria conjugate vaccine , haemophilus b tetanus conjugate vaccine , havrix , havrix obsolete ; , havrix pediatric , havrix pediatric obsolete ; , hepatitis a adult vaccine , hepatitis a pediatric vaccine , hepatitis a vaccine obsolete ; , hepatitis b vaccine , hibtiter , hibtiter obsolete ; , histolyn-cyl , histoplasmin , histoplasmin diluted , hivid , hpv , human papillomavirus vaccine , hycamtin , hydralazine , hydroxychloroquine , hypericum perforatum , ilosone , ilotycin gluceptate , imatinib , imovax rabies , imovax rabies obsolete ; , imovax rabies obsolete ; , imuran , infergen , influenza virus vaccine, inactivated , inh , interferon alfa-2a , interferon alfa-2b , interferon alfa-n1 , interferon alfa-n3 , interferon alfacon-1 , intron a , invirase , iodoquinol , ipol , ipv , isoniazid , itraconazole , ixabepilone , ixempra , japanese encephalitis virus vaccine , je-vax , kepivance , ketek , ketek pak , kineret , lapatinib , lescol , lescol xl , leukine , levaquin , levaquin leva-pak , levofloxacin , lexiva , lipitor , liquid pedvaxhib , lomefloxacin , lopurin , lovastatin , lovastatin extended release , luvox , lyme disease vaccine , lymerix , macrobid , macrodantin , maxaquin , menactra , meningococcal conjugate vaccine , meningococcal polysaccharide vaccine , menomune a c y w-135 , mephenytoin , mesantoin , metastron , metro , metrocream , metrogel , metrogel-vaginal , metrolotion , metronidazole , metronidazole extended release , metronidazole topical , metryl , mevacor , mibefradil , miconazole , mifeprex , mifepristone , mitomycin , mixed respiratory vaccine , monascus , monistat , mono-vacc test ; , moxifloxacin , msta mumps skin test antigen , multihance , multitest cmi , mumps skin test antigen , mutamycin , my-e , myambutol , myochrysine , nalidixic acid , navelbine , nefazodone , neggram , nelarabine , nelfinavir , neulasta , neupogen , nilotinib , nitro macro , nitrofurantoin , nitrofurantoin dual release , nitrofurantoin macrocrystals , nitrofurantoin regular release , norfloxacin , noritate , noroxin , norvir , norvir soft gelatin , noxafil , nydrazid , ofloxacin , omnihib , onxol , oxaliplatin , oxcarbazepine , paclitaxel , paclitaxel protein-bound , palifermin , paraplatin , pce dispertab , pedvax hib , peganone , pegasys , pegfilgrastim , peginterferon alfa-2a , peginterferon alfa-2b , pegintron , pegintron redipen , penetrex , phenytek , phenytoin , phenytoin extended release , phenytoin sodium, prompt , plague vaccine , plaquenil sulfate , platinol-aq , pneumococcal 23-valent vaccine , pneumococcal 23-valent vaccine obsolete ; , pneumococcal 7-valent vaccine , pneumovax 23 , pneumovax 23 obsolete ; , pnu-imune 23 obsolete ; , podocon-25 , pododerm , podofin , podophyllum resin topical , poliovirus vaccine, inactivated , posaconazole , posicor , pravachol , pravastatin , prevnar , priftin , prograf , prohibit , proquin xr , protostat , quineprox , rabavert , rabavert obsolete ; , rabies vaccine obsolete ; , rabies vaccine, human diploid cell , rabies vaccine, purified chick embryo cell , rapamune , raptiva , raxar , recombivax hb , recombivax hb adult , recombivax hb dialysis formulation , recombivax hb pediatric adolescent , red yeast rice , retrovir , rezulin , ridaura , rifapentine , ritonavir , robimycin , roferon-a , rosuvastatin , rozex , ru-486 , saquinavir , saquinavir mesylate , sargramostim , sclavo test-ppd , serzone , simvastatin , sirolimus , skin test antigens, multiple , sodium phosphate p32 , solganal , sparfloxacin , spherulin , spl , sporanox , sprycel , st and fosamprenavir.
The use of certain medications should be severely restricted. 1. The use of benzodiazepine agents in emergency situations will not exceed a 24hour period without review and documentation of reason s ; for continuation of the medication. The use of benzodiazepine agents in non-emergency situations will not exceed a 3-week period, including taper and discontinuation. If a youth is considered appropriate for re-prescription of benzodiazepines within any 3month period, consultation with a second psychiatrist will be obtained and documented. When benzodiazepines are prescribed, documentation of any history.
|
INTRODUCTION Rabies has been considered one of the greatest terrors of humankind throughout history7. It has a worldwide distribution, being reported in all continents, except Antarctica21. In Brazil, the disease is endemic, with an incidence estimated at 0.05 per 100, 000 population. The northeast region was responsible for more than 50% of all cases registered in the country from 1986 to 200114. Rabies is an acute viral encephalomyelitis caused by etiologic agents in the family Rhabdoviridae, genus Lyssavirus 2, 8, 18, . Transmission occurs through animal bites, mainly by dogs2, 10, 21. The incubation period ranges from one to three months, but the disease can occur years after the exposure21. Renal involvement in rabies is not well described in the literature. Acute renal failure in rabies seems to be rare, with few documented cases of oliguria, without demonstration of alterations in serum creatinine or glomerular filtration rate4, 13. The involvement of extraneural organs in rabies has been reported, including skeletal and cardiac muscle, adrenal glands and pancreas11, 23. At the present time no study has described histopathologic changes in renal tissue in rabies. The studies in which the kidneys were examined found no abnormality11, 15. A recent publication has demonstrated the transmission of rabies and fosrenol.
From the cell surface promoted apoptosis.42 Thus, in the present studies, we showed that GC apoptosis was associated with the cleavage of the extracellular domain of the N-cadherin molecule and that prevention of this molecular event was specifically capable of preventing apoptosis as assessed by a number of independent experimental methods. Taken together, the present data provide strong evidence that N-cadherin-mediated cell-cell adhesion is critical for the survival of GCs. The signaling cascade following the homotypic homophilic interactions between N-cadherin molecules on aggregating GCs remains to be elucidated. Despite the variability of the extracellular domain between different cadherins, all members of this family possess a highly conserved cytoplasmic domain that functions as a binding site for catenins, which mediate binding to the cytoskeleton. It is possible that occupation of the cell recognition site on the extracellular domain is followed by activation of signal transduction pathways ultimately leading to up-regulation of survival factors. In support of this hypothesis is the interaction of N-cadherin with catenins that was recently shown to promote cell viability.43 Alternatively, it is possible that occupation of the extracellular domain of N-cadherin induces conformational changes in the cytoskeleton and cell shape that might provide nonspecific signals promoting cell survival. Cleavage of the molecule by metalloproteinases may result in the withdrawal of these nonspecific supporting mechanisms, leading the cell to apoptosis. In any case, regulation of N-cadherin expression by extracellular proteolysis provides for a number of theoretical possibilities for modulation of cell adhesive interactions participating in the survival of human GCs. If the expression and or the activity of an N-cadherin cleaving proteinase can be controlled locally, this could provide an additional mechanism for the fine-tuning of the GC position, cell-cell contact, and survival of the cell and hence the follicle or corpus luteum. In summary, the present studies have shown that Ncadherin is expressed by human GCs and that this molecule mediates cell-cell adhesion between GCs. We observed a strong correlation between N-cadherin expression by granulosa or luteal cells and follicular survival in isolated follicles and archival tissue sections. In fact, we found strong expression of the molecule by GCs in follicles of the resting pool, of growing antral follicles, and of healthy corpora lutea. In contrast, the molecule was lost in degenerating GCs of atretic follicles and in luteal cells of the late luteal phase. Furthermore, we demonstrated that cell-cell adhesion is critical to the survival of GCs and that N-cadherin-mediated cell-cell adhesion is a critical mediator of survival signals and inhibits apoptosis in these cells. Our data provide two possible mechanisms by which apoptosis may be triggered in GCs, namely, through cAMP-mediated pathways that also induce down-regulation of N-cadherin and through the enzymatic cleavage of the extracellular domain of the molecule. Taken together, our experimental observations strongly support the concept that this adhesion molecule may be intimately involved in determining the fate of follicles and of the corpus luteum. Specifically, we pro.
Table 2 Anguilla anguilla. Sampling location of genetic structure analysis with microsatellite markers including . country, sampling location, code, sampling period, life stage G glass eel, Y yellow eel, S silver eel ; and sample size N ; . Country Belgium Denmark Denmark Denmark England England England England Finland France France France France France France Greece Iceland Ireland Ireland Ireland Italy Italy Italy Lithuania Morocco Morocco Morocco The Netherlands Norway Portugal Portugal Portugal Spain Sweden Sweden Sweden Sweden Sweden Sweden Tunisia Yugoslavia Sampling location IJzer Guden Kolding Vester Vedsted Chelmer Parret Severn Stour Kokemenjoki Loire Arzal Frmur Gironde Salses Leucate Tour-du-Valat Sagiada lvus Burrishoole Erne Feale Po Martha Tibern Curonian lagoon Moulouya Oued Lockkos Sebou Den Oever Imsa Minho Mira Sisandro Asturias Dallven Ellensjn Lagan Motala Ringhals Viskan Mdierda Bojana Code BE DE1 DE2 DE3 EN1 EN2 EN3 EN4 FI FR1 FR2 FR3 FR4 FR5 FR6 GR IC IR1 IR2 IR3 IT1 IT2 IT3 LI MO1 MO2 MO3 NE NO PO1 PO2 PO3 SP SW1 SW2 SW3 SW4 SW5 SW6 TU YU Sampling period 1994 2001 Life stage G G G and fragmin.
Term Details Acute myocardial infarction Angina pectoris Aspirin Aspirin [antiplatelet] Aspirin on prescription Aspirin Prophylaxis over the counter therapy Atherosclerosis Atherosclerotic cardiovasc disease Ischaemic cardiomyopathy Silent myocardial ischaemia Other specific chronic IHD Other chronic IHD NOS Atorvastatin Atrial fibrillation flutter Body Mass Index Captopril Cerebral arterial occlusion Cerivastatin Cilazapril Coronary atherosclerosis Enalapril Maleate Fluvastatin Fosinopril Sodium Heart failure Intracerebral haemorrhage Lisinopril Moexipril Hydrochloride O E - blood pressure reading Old myocardial infarction Over the counter aspirin therapy Perindopril Tert-Butylamine Postmyocardial infarction syndrome Postoperative MI Pravastatin Precerebral arterial occlusion Preinfarction syndrome Quinapril Ramipril Term ID G30% G33% Emis Code 167 BNF 2.9 Emis Code EMISAS1 Emis Code EGTONAS1 G70% G342 G34z.
Vadose zone water potential was measured in six watersheds at the end of the 1997 summer season, the driest time of year in the SDEF. Rainfall for this year was 711 mm, close to the long-term average. The channel, side-slope, and summit elements were sampled in three watersheds of each vegetation type during September 1997. Because of a rainstorm in the middle of sampling, additional samples of the upper 20 cm the approximate depth of wetting from the September storm ; were measured in November 1997 after a dry period. Samples were collected in known increments usually 10 cm ; to the depth allowable by hand auger, including the soil and underlying weathered rock. Regolith water potential was compared rather than water content to relate to plant usage and minimize differences due to regolith properties. Water potential was determined for each depth increment sampled and was calculated from regolith water activity as determined by a chilled-mirror dew point technique on a Decagon Devices, Inc. Pullman, WA ; Aqualab CX-2 Rawlins and Campbell, 1986 ; . For soils sampled immediately after the September storm, data reported for the upper 20 cm are from the November sampling. Vadose zone and frova and fluvastatin.
The composite end-point was reached in 33% of the fluvastatin patients and 36% of the placebo patients P 024 ; . Analysis of this composite end-point at 6 weeks as well as analysis on the basis of the presence of baseline ischaemia on AECG revealed no difference with regards to treatment effect.
In this study we aimed at analysing the stabilizing effects of fluvastatin on the blood– brain barrier bbb ; integrity, using an in vitro co-culture model of ecv304 and c6, or primary bovine endothelial cells and rat astrocytes and frovatriptan!
LTI Plan 1998 and LTI Plan 2000: The LTI 1998 and LTI 2000 stock option plans are variable award plans. Compensation costs under IFRSs are measured on the basis of the estimated performance of the Schering AG share price and the performance of a benchmark index DAX and STOXX Healthcare ; . The costs of the LTI Plans 1998 and 2000 have been largely hedged by the purchase of Schering AG call options. Under U.S. GAAP, compensation costs are recognized over the three-year vesting period on the basis of the fair value of Schering AG shares and the benchmark index at the respective balance sheet dates. Under U.S. GAAP, the acquisition costs of the Schering AG call options are deducted from equity, and the proceeds from the sale of the options are credited directly to equity. Under IFRSs, the accumulated compensation costs are shown as a liability. Under U.S. GAAP, these costs are part of equity. LTI Plans 2001 I and II: The "Top Executives" plans are designed as variable award plans. Compensation costs under IFRSs are measured on the basis of an estimate of the outcome of the performance conditions at each balance sheet date by utilizing option pricing models. Under U.S. GAAP, compensation costs are measured at the fair value of Schering AG shares at the respective balance sheet dates. The plans are designed as stock appreciation right plans. At exercise, the award will be settled by a cash payment amounting to the difference between the market price of Schering AG shares at the date of exercise and the exercise price. Compensation costs are therefore accrued as a liability under both IFRSs and U.S. GAAP. "Key Managers" plans are fixed award plans. No costs are recognised under both IFRSs and U.S. GAAP. LTI Plans 2001 III and 2004: The costs of the plans have been hedged by the purchase of Schering AG call options. Under both IFRSs and U.S. GAAP, changes in fair value are recognized as gain or loss, while the costs calculated at the date of grant are accrued over the three-year vesting period. k. ; Tax effect on U.S. GAAP adjustments This reconciliation item includes all tax effects due to the aforementioned reconciling items, except the adjustment relating to the equity method Aventis CropScience ; , which is presented net of tax. l. ; Minority Interest According to IAS 1 "Presentation of Financial Statements", a minority interest must be presented within equity. Under U.S. GAAP, a minority interest is not part of equity. 38 ; Additional U.S. GAAP information SFAS No. 130 "Reporting Comprehensive Income" SFAS No. 130 "Reporting Comprehensive Income" requires the reporting of all changes in shareholders' equity except those resulting from investments by or distributions to shareholders.
Mean cost per dose. The mean cost per statin dose was computed using the wholesale acquisition cost published in the Drug Topics Redbook Update for February 2001. Prices for each brand and dosage strength are listed in Table 3. Using a constant price for each dosage strength throughout the two-year period, any changes in the mean cost per dose are attributable to changes in brand share and dosage-mix only. The mean cost per dose is shown in Table 4 for the weighted average of the 1, 070 plans in the database and for fee-forservice customers. Discounts offered to HMOs were not taken into account. The lower price in the fee-for-service sector is due to a slightly higher share for cerivastatin 8.2 percent in fee-for-service vs. 5.7 percent in managed care plans ; and fluvastatin 6.6 percent vs. 5.8 percent ; and a higher dosage mix for 10-mg atorvastatin 62.3 percent vs. 57.4 percent ; . This indicates that the fee-for-service market is slightly more cost-sensitive, as expected. Table 5 shows the contribution of each brand to the overall increase in cost per dose of about 6 cents from.
Our data demonstrate that this inhibition is dose dependent, with the highest effect at a concentration of 0.1 cerivastatin ; , 2.5 simvastatin ; and 1 Amol l fluvastatin ; , respectively. 3.3. Statins prevent HUVEC proliferation induced by oxLDL and LPC To investigate whether oxLDL- and LPC-induced proliferation could be blocked by the antiproliferative effect of the statins, we incubated HUVEC with both substances. LPC and oxLDL were applied in concentrations with the highest proliferative effect LPC 20 Amol l, oxLDL 10 Ag ml ; Fig. 3 summarizes the data obtained from cell counts and [3H]-thymidine incorporation assay after a combined treatment of HUVEC with oxLDL, LPC and cerivastatin, or.
Cells were loaded with 1 p~ Fura 2 AM, washed, and suspended in HBSS without calcium. Fluorescence was measured following exci0M tation at 340 or 380 nm and 50 CdC12, 50 digitonin, or 1m EGTA were added as noted on the figure. The scale and dashed line show the 340 380 fluorescence ratio, and the horizontal bar 1 min.
Fig. 6. Inhibitory effect of wortmannin Wt ; on increased phosphorylation of Akt in mesenteric arteries by in vivo treatment with Flv of 10-h septic rabbits. Wortmannin 1 mg kg ; was intravenously injected 1 h after LPS. A, representative Western blots of phospho-Akt at Thr308 top ; and at Ser473 middle ; and of total Akt bottom ; 10 h after induction of sepsis when treated with fluvastatin and fluvastatin wortmannin in comparison with those obtained in sepsis alone. B and C, bar graphs summarizing the immunoblot data. To standardize between experiments, an arbitrary density of 1 was assigned to be the band obtained from the vascular sample of the 10-h septic rabbit. Values are means S.E. n 5 ; of phospho-Akt at Thr308 B ; and at Ser473 C ; Akt, expressed relative to the respective result from sepsis alone. , P 0.05 versus 10 h of sepsis alone; #, P 0.05 versus sepsis with fluvastatin treatment and focalin.
Cheap fluvastatin
Do not take fluvastatin without first talking to your doctor if you are breast-feeding a baby.
Figure 5. RF profiles A, B ; of early.
The following guidelines are for arranging drugs.
Chen H, Ikeda U, Shimpo M, Ikeda M, Minota S, and Shimada J 2000 ; Fluvastatin upregulates inducible nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells. Hypertension 36: 923-928. Chyu KY, Dimayuga P, Zhu J, Nilsson J, Kaul S, Shah PK, and Cercek B 1999 ; Decreased neointimal thickening after arterial wall injury in inducible nitric oxide synthase knockout mice. Circ Res 85: 1192-1198. Fukumoto Y, Shimokawa H, Kozai T, Kadokami T, Kuwata K, Yonemitsu Y, Kuga T, Egashira T, Sueishi K, and Takeshita A 1997 ; Vasculoprotective role of inducible nitric oxide synthase at inflammatory coronary lesions induced by chronic treatment with interleukin-1 in pigs in vivo. Circulation 96: 3104-3111. Goldstein JL and Brown MS 1990 ; Regulation of the mevalonate pathway. Nature 343: 425-430. Guijarro C, Blanco-Colio LM, Ortego M, Alons V, Ortiz A, Plaza JJ, Daz C, Hernndez G, and Egido J 1998 ; 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 83: 490-500. Hausding M, Witteck A, Rodriguez-Pascual F, Von Eichel-Streiber C, Forstermann U, and Kleinert H 2000 ; Inhibition of small G proteins of the Rho family by statins or Clostridium difficile toxin B enhances cytokine-mediated induction of NO synthase II. Br J Pharmacol 131: 553-561.
Lemos p, et al fluvastatin prevents cardiac events following successful percutaneous coronary intervention in patients with multivessel disease: the lescol intervention prevention study.
Proprietary Medicinal Products. One factor that may influence the magnitude of the IDenabled dose sparing effect is the level of pre-existing antibodies at the time of immunization 6, 10, 24 ; . Thus, it will be of interest to examine microneedle delivery systems in various age groups and in subjects both with and without pre-existing antibodies against the vaccine strains. The successful clinical and commercial.
Saying that for the ultimate good of the state, many parents need to murder their living and unborn children. 9.
Cheap fluvastatin online
Local PES have large autonomy in policy-mix and design of active measures which was increased by 1998 reforms ; , but the organisational model is centrally determined through the national headquarters; at the end of 2002, all employment should have implemented the new organisational model `Employment Office 2000'. 5.4 Performance assessment Performance assessment is a decisive stage in MBO since it will determine whether any and what kind of consequences follow from relatively ; good or bad performance. Moreover, the MBO model stresses not merely post hoc performance assessment but continuous 'real time' monitoring of performance in order to identify and correct performance shortfalls. The impact of performance assessment is not, however, `automatic', it depends in particular on performance incentives for individuals and operating units. Moreover, performance assessment will be probably more accepted and `legitimate' when it is clear and understandable. In this section we compare and discuss the forms of performance assessment practiced by these countries within their MBO-cycle. First of all, all four case study countries and also Germany56 ; have an obligatory stage of performance assessment built into the MBO-approach, on basis of the final results. In three of them, Great Britain, France, and Sweden, there is a strong emphasis on on-going performance monitoring by the head office, but not in Austria because of the much more decentralized philosophy of the MBO system. In Great Britain, performance assessment is highly institutionalized in a central Jobcentre Performance Unit at head office and in regular meetings between the different organizational levels. At the national level, ES performance achievement of target levels aimed at ; is reviewed quarterly by the Ministry. At regional, district and local jobcentres' level, performance is reviewed monthly by the respective higher unit level. Furthermore, individual managers and employees' performance are considered in individual end-of-year reviews. In the ES the emphasis is strongly on on-going performance assessment based largely on quantitative information on performance against targets and real time response to problems rather than on post hoc assessment of performance e.g. in Austria ; or regular qualitative policy reviews of regional.
Fluvastatin sodium is the first entirely synthetic hmg-coa reductase inhibitor, and is in part structurally distinct from the other compounds of this therapeutic class.
Hepatitis B virus HBV ; is one of several viruses that cause hepatitis. HBV is a double stranded DNA virus with three major antigens known as hepatitis B surface antigen HBsAg ; , hepatitis B e antigen HBeAg ; and hepatitis B core antigen HBcAg ; . The presence of HBsAg can be detected in serum 30 to 60 days after exposure and persists until the infection resolves. The incubation period for hepatitis B is 45 160 days average 120 days ; . Antibody to hepatitis B surface antigen anti-HBs ; appears in serum after the infection has resolved and confers long-term immunity. In a proportion of cases, which varies inversely with age, infection persists and this protective antibody is not produced. HBcAg never appears in serum. Anti-HBc develops in all HBV infections, is not protective and persists indefinitely. Anti-HBc IgM is a marker of recent HBV infection. HBeAg in serum is associated with viral replication and high levels of infectiousness. Anti-HBe indicates loss of replicating virus and lower infectiousness. Any serum containing HBsAg, however, is considered infectious. HBV infection is usually associated with exposure to blood or infectious bodily fluids. Common means of transmission include heterosexual and homosexual contact, injection drug use, and perinatal transmission mother to infant ; . The risk of transfusion-related hepatitis B is extremely low because of routine HBsAg screening of donated blood and rejection of donors at risk of infection. Infections also occur in settings of close personal contact through unrecognized contact with infective fluids. In about 35% of cases, no risk factors can be identified. Initial infection with HBV may be asymptomatic in up to 50% of cases, or symptomatic. Acute illness may last up to 3 months and has a case-fatality rate of 1% to 2%. An individual with either acute symptomatic or asymptomatic HBV infection may become a chronic carrier. A chronic carrier is an individual from whom serum samples taken 6 months apart are HBsAg positive or a single serum sample is HBsAg positive and anti-HBc IgM negative. The risk of becoming a chronic carrier varies inversely with the age at which infection occurs infants 90% to 95% risk; children 5 years 25% to 50%; adults 6% to 10% ; . The risk of becoming a chronic carrier is also greater in immunocompromised patients. Chronic carriers often do not have overt disease, but over time are at increased risk for hepatic cirrhosis and hepatocellular carcinoma. Chronic carriers are likely the major source of infection, and all carriers should be considered infectious. Although there are no national data on the prevalence of chronic HBV infection for the whole Canadian population, Canada is considered an area of low endemicity. It is estimated that less than 5% of residents have markers of past infection and less than 0.5% are HBsAg carriers. There are, however, specific segments of the population that.
Prevalence of co-morbidities at presentation included: ischaemic heart disease 31%, cardiac dysfunction 24%, hypertension 93%, current smoking 31%, peripheral vascular disease 23%, proliferative retinopathy 82%, registered blind 17%, symptomatic autonomic neuropathy 29%, malignant disease 7%. Transplant recipients were statistically significantly P 0.05 ; younger and, as a group, had had a statistically significantly lower prevalence of ischaemic heart disease and cardiac dysfunction at initiation than those not receiving an allograft. Survival was also greater in this group. When the effects of age and co-morbidity were incorporated into a model of survival of those not receiving an allograft, no independent effect of modality of renal replacement therapy was detected. Pneumonia with renal failure in the ITU: case series T. Collidge, M. A. McMillan on behalf of the Renal Unit; Western Infirmary, Glasgow G11 6NT Acute renal failure in the intensive therapy unit ITU ; is often attributed to acute tubular necrosis, with less renal investigation than customary in a Renal Unit. We report three cases over a 1-year period, where patients admitted to our ITU with pneumonia and renal failure were later found to have paraproteinaemia. The clinical findings and delays in diagnosis are discussed. Paraproteinaemia should be suspected in patients with pneumonia and acute renal failure. A presumptive diagnosis of acute tubular necrosis does not remove the need for investigation of acute renal failure. Fluvastatin inhibits human immune cell function Mark Hadden1, Alan Mcintyre1, Hilary Marshall2, Alan Jardine2, Mark MacGregor3; 1Transplantation Laboratories and 2Department of Medicine, Western Infirmary, and 3Renal Unit, Stobhill General Hospital, Glasgow At least 50% of transplant recipients have hyperlipidaemia. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors HMGRI ; are commonly used to lower cholesterol. They also reduce acute rejection rates and improve survival in heart and kidney transplant patients treated with cyclosporin. In vitro work shows that HMGRI inhibit NK cell cytotoxicity and T cell proliferation in a cholesterol-independent manner, by inhibiting isoprenylation of cellular signalling proteins. This study examines the effect of fluvastatin on NK cell cytotoxicity, T cell proliferation, and LFA-1 expression in human lymphocytes, in vitro. Mevalonate, added 2 h prior to assay, and farnesyl transferase inhibitor were used to elucidate the mechanism of these cholesterol-indepentent effects. Fluvastatin was chosen because it undergoes least interaction with the immunosuppressant cyclosporin, giving it the most favourable side effect profile of all the HMGRI. NK cells and T cells were isolated from the blood of normal volunteers and cultured on flat-bottomed plates over a set time-scale. NK cell cytotoxicity was determined using 51Chromium-labelled target cell assay. T cells were stimulated to proliferatie using cross-linked antiCD3, and proliferation quantified using [3H ] thymidine incorporation. LFA-1 expression was determined using FACS. Fluvastatin inhibited NK cell cytotoxicity at days 1, 4 P 0.0028 ; , and 7 P 0.0009 ; . Mevalonate reversed inhibition at all time points Significance was reached at day 4, P 0.0l4 and 7 P 0.035 ; . T cell proliferation was inhibited at days 1, 3 P 0.005 ; , and 5 P 0.005 ; . Mevalonate did not reverse inhibition. FTI had no effect on NK or cell functions and did not inhibit mevalonate reversal. From this experimental protocol we could not con.
|
|
|
